Strata Mental Health Solutions Awarded Compass Pathways Grant to Develop U.S. Provider Training for COMP360
Strata Mental Health Solutions, an expert-led training and implementation partner focused on preparing clinical networks to deliver regulated psychedelic treatments, has been selected as one of five U.S. healthcare provider training organizations to receive a training grant from Compass Pathways plc (Nasdaq: CMPS).
The grant will support Strata’s development of healthcare provider training programs for COMP360, Compass Pathways’ investigational psilocybin treatment, should the therapy receive regulatory approval. The initiative is intended to help prepare healthcare providers and clinical networks for the potential introduction of psychedelic-assisted treatment into regulated mental healthcare settings.
Strata’s selection builds on an existing relationship with Compass Pathways. The company’s founders previously worked with Compass on the development of the provider training program used during COMP360 clinical trials. Strata’s team also brings experience training clinicians and supporting direct patient care involving psychedelic treatments in regulated clinical environments.
The new grant-funded program is designed to translate the clinical practices and treatment standards established during the COMP360 clinical development program into structured training and implementation support for healthcare providers preparing for potential commercial use.
Preparing Providers for a New Model of Psychiatric Care
Psychedelic-assisted treatments represent a fundamentally different approach to the delivery of many conventional psychiatric medicines.
Rather than being administered through a short appointment or routine medication-management visit, psychedelic treatments can involve multi-hour medication administration sessions in which patients are supported by trained clinical teams. Treatment may also involve preparation sessions before medication administration and follow-up or integration support afterward.
This model requires healthcare providers and clinics to establish specialized workflows and multidisciplinary capabilities.
Clinical teams must understand how to prepare patients for treatment, monitor them during extended administration sessions and provide appropriate follow-up care. Clinics also need procedures for patient screening, safety monitoring, escalation and quality assurance.
Strata’s training program will be designed around this broader treatment model.
The company said its approach will draw directly from the model used during COMP360 clinical trials. Training will be delivered by clinical faculty with direct experience in the COMP360 development program, giving providers an opportunity to learn from clinicians familiar with the treatment approach used in research settings.
The objective is to help ensure that the transition from clinical research to potential real-world treatment does not result in a reduction in clinical standards.
Mark Burton, PhD, Co-Founder and CEO of Strata Mental Health Solutions, said clinics are increasingly interested in the potential of psychedelic treatments but also want guidance on how to deliver them safely and responsibly.
According to Burton, Strata’s approach is to begin with the methods and standards established during clinical trials and build the real-world implementation framework from that foundation.
He emphasized that the company’s central objective is to ensure that the standard of care established during research is maintained when a treatment potentially moves into routine clinical practice.
Compass Pathways Advances COMP360 Development
The training initiative comes as Compass Pathways continues to advance the clinical and regulatory development of COMP360.
Compass has reported positive results from two Phase 3 trials evaluating COMP360. The company expects its New Drug Application submission to be completed in the fourth quarter of 2026 through a rolling submission and FDA review pathway.
Subject to regulatory review and approval, Compass expects a potential commercial launch in the first half of 2027.
Because COMP360 remains investigational and has not been approved for commercial use based on the information provided, the Strata training program is being developed in anticipation of a potential regulatory authorization rather than as training for an already approved therapy.
The grant program established by Compass is intended to help prepare healthcare providers for the delivery of COMP360 if it is approved.
For Strata, the initiative represents an opportunity to use its clinical training and implementation expertise to help establish infrastructure that could support psychedelic treatment delivery at scale.
Translating Clinical Trial Experience Into Practice
One of the central elements of Strata’s approach is the use of clinical trial experience as the foundation for provider education.
The company plans to develop a structured training and certification program for multidisciplinary treatment teams. The program will be delivered through Strata’s learning platform and supplemented by live practice with clinical faculty.
The training is intended to equip clinicians with core competencies needed to work within a psychedelic treatment model.
Rather than focusing solely on the pharmacological characteristics of the investigational treatment, the program addresses the broader care environment surrounding psychedelic administration.
This includes preparing treatment teams to work collaboratively throughout the patient journey, from pre-treatment preparation through medication administration and post-treatment support.
The approach reflects the complexity of administering psychedelic therapies in controlled clinical settings, where patient experience, clinical monitoring and team coordination can all play important roles.
Strata said treatment teams participating in its program will receive support modeled on the support provided to teams involved in the clinical trials. The goal is to help establish consistency between the standards used during research and those applied in future real-world treatment environments.
Site Readiness Extends Beyond Provider Training
The grant-funded provider education program is one component of Strata’s broader implementation platform.
The company’s services extend beyond individual clinician training to preparing healthcare facilities and clinical networks for psychedelic treatment delivery.
Through its site-readiness consultation, Strata works with clinics to evaluate the operational infrastructure required to introduce psychedelic treatments.
This includes workflows, patient screening procedures, escalation pathways and quality assurance processes. The company said its site-readiness approach is designed to exceed anticipated Risk Evaluation and Mitigation Strategy, or REMS, requirements.
REMS programs are used by the U.S. Food and Drug Administration for certain medicines where additional safety measures are needed to ensure that the benefits of a therapy outweigh its risks.
Although specific regulatory requirements for COMP360 would depend on the FDA’s eventual decisions, Strata is developing its implementation framework with anticipated regulatory and operational requirements in mind.
The company’s support does not end when a clinic completes its initial training. Strata plans to continue supporting clinical networks as they begin real-world treatment delivery through case-based supervision and ongoing clinic support.
This model is intended to help clinical teams move from theoretical training to practical implementation while maintaining established standards of care.
Building a Scalable Psychedelic Treatment Infrastructure
The potential emergence of approved psychedelic treatments could create new requirements for healthcare systems across the United States.
Mental healthcare organizations that eventually offer these therapies may need to develop dedicated spaces, specialized workflows and multidisciplinary teams capable of supporting lengthy treatment sessions.
They may also need to establish procedures for determining which patients are appropriate candidates, managing potential clinical concerns and ensuring continuity of care before and after treatment.
Strata’s implementation platform is designed to address these operational considerations.
By combining provider education, certification, site-readiness consultation, clinical supervision and ongoing support, the company aims to give healthcare networks a comprehensive framework for introducing regulated psychedelic treatments.
The platform is also intended to support future therapies as they potentially enter the market.
This broader strategy could become increasingly relevant as pharmaceutical and biotechnology companies advance psychedelic compounds through clinical development. Each treatment may have different clinical characteristics and regulatory requirements, but healthcare organizations may be able to build on foundational capabilities related to patient preparation, multidisciplinary care and treatment-site operations.
Focus on Responsible Dissemination
Strata’s emphasis on clinical standards reflects the challenges associated with moving psychedelic treatments from controlled research environments into broader clinical practice.
Clinical trials operate under structured protocols, with trained investigators, defined patient populations and carefully monitored treatment environments. Commercial healthcare settings are typically more diverse, with providers and facilities varying in experience, resources and workflows.
Creating standardized education and implementation processes can therefore help clinical networks prepare for the operational demands of psychedelic treatment.
Strata said its training will be based on the approach used in the COMP360 clinical development program and taught by faculty with direct experience with the program.
The company believes this approach can help healthcare providers develop the knowledge and practical skills necessary to deliver treatment responsibly.
Stephanie Knatz Peck, PhD, Co-Founder and Chief Clinical Officer of Strata Mental Health Solutions, said the company’s objective is to empower mental healthcare systems throughout the United States to deliver high-quality psychedelic treatments to patients who may need new treatment options.
She said Strata is developing a program intended to equip providers with core competencies based on the company’s experience working with psychedelic compounds in clinical trial settings.
Five U.S. Training Partners Selected
Strata is one of five U.S. healthcare provider training organizations selected by Compass Pathways to participate in the grant program.
The program reflects Compass’ efforts to prepare the healthcare infrastructure that could be needed if COMP360 receives regulatory approval.
Provider training is an important component of potential treatment commercialization because approval of a novel therapy does not by itself create the clinical infrastructure required to administer it safely and effectively.
Healthcare providers must understand the treatment protocol, while organizations need operational systems capable of supporting patients throughout the treatment journey.
The training-partner initiative is intended to help address those requirements ahead of a potential launch.
For Strata, the award also reinforces its position as a specialized training and implementation partner for clinical networks interested in regulated psychedelic medicine.
Compass Pathways expects to complete its COMP360 NDA submission during the fourth quarter of 2026 through a rolling submission and FDA review pathway. If approved, the company expects commercial launch during the first half of 2027.
The timing places increasing importance on provider and clinic preparation as the development program moves toward potential regulatory review and commercialization.
Strata’s work under the grant is intended to help ensure that healthcare organizations have an appropriate training and implementation framework if COMP360 becomes available.
However, COMP360 remains an investigational treatment, and future availability depends on regulatory review and approval. The training initiative does not itself represent regulatory authorization of the therapy.
As the psychedelic medicine field continues to evolve, the development of appropriate clinical infrastructure is likely to remain an important consideration for healthcare systems.
Strata’s model seeks to address this need by combining clinician training with site preparation, practical supervision and continuing implementation support.
Expanding Access Through Clinical Readiness
The selection of Strata Mental Health Solutions as one of Compass Pathways’ five U.S. training grant recipients marks an important step in the company’s efforts to prepare providers for potential psychedelic treatment delivery.
The initiative combines Strata’s experience in clinician education and regulated psychedelic care with Compass Pathways’ ongoing development of COMP360.
At the center of the program is the principle that clinical standards established during research should continue into real-world care. By using the COMP360 clinical trial model as a foundation for training, Strata aims to prepare multidisciplinary teams for the unique requirements of psychedelic treatment.
Its broader implementation platform extends this preparation to the clinic level through site-readiness assessments, workflow development, screening procedures, escalation pathways, quality assurance and ongoing case-based supervision.
Together, these capabilities are intended to help healthcare networks build the infrastructure necessary to responsibly introduce psychedelic treatments if and when they receive regulatory approval.
With COMP360 advancing through Phase 3 development and Compass Pathways anticipating completion of its NDA submission in the fourth quarter of 2026, the training initiative comes at a pivotal stage for the potential emergence of regulated psychedelic treatment in the United States.
Strata’s work will focus on ensuring that providers and clinical networks are prepared to deliver these treatments within structured, evidence-based and professionally supported environments, helping bridge the gap between clinical research and potential real-world mental healthcare delivery.
About Strata Mental Health Solutions
Strata is the expert-led implementation partner preparing clinical networks to deliver psychedelic treatments. Its team developed and implemented the provider training program for COMP360, trained thousands of clinicians across psychedelic treatment models, and directly treated hundreds of patients across pivotal psychedelic clinical trials. Strata’s training, certification, and site-readiness programs connect with the systems clinics already use, so treatment teams can deliver new treatments safely from day one, at the standard set in the trials. Learn more at www.stratamentalhealth.com.